160
Participants
Start Date
October 1, 2022
Primary Completion Date
June 30, 2025
Study Completion Date
December 31, 2025
alirocumab
In the PCSK9 inhibitor group, a dose of PCSK9 inhibitor (alirocumab,75mg) was injected subcutaneously immediately after PPCI and was administered every two weeks thereafter for 3 months
conventional treatment
conventional treatment were given according to international uniformguidelines
RECRUITING
nineth people's hospital, School of Medicine, shanghai jiaotong university, Shanghai
RECRUITING
Shanghai chest hospital, Shanghai
RECRUITING
Shanghai tongren hospital, Shanghai
RECRUITING
tenth people's hospital, tongji university, Shanghai, Shanghai
RECRUITING
Songjiang hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai
Collaborators (1)
China Cardiovascular Association
OTHER
Shanghai Tong Ren Hospital
OTHER